polydipsia as CDI, as inappropriate therapy with desmopressin can lead to dangerous hyponatraemia in patients who continue to drink excessively.
In this review, we will summarise the various diagnostic tests used to make the biochemical diagnosis of CDI, and the biochemical and radiological tests needed to identify the causation of AVP deficiency. We will also review the treatment strategies to manage polyuria, while avoiding hyponatraemia.
| C AUS E S OF CENTR AL D IAB E TE S INS IPIDUS
Central DI is the clinical manifestation of destruction of the neurons of the hypothalamus/posterior pituitary axis, with consequent loss of AVP secretion. The syndrome is caused by a wide variety of acquired or congenital lesions.
The vast majority of CDI cases in our unit occur secondary to neurosurgical conditions (Table 1) . Pituitary tumours almost never cause CDI de novo, but DI occurs in 20% of patients following transsphenoidal surgery, due to interruptions in the hypothalamicneurohypophyseal neuronal connections. DI is typically transient, occurring within 24-48 hours of surgery, and settles within 2-5 days; persistent DI is rare. 1 Rarely, a triphasic response can occur in which initial DI is followed by a transient period of hyponatraemia and antidiuresis, due to unregulated release of AVP from degenerating neurohypophyseal tissue. This is followed by a return to permanent DI up to 2 weeks postoperatively when AVP stores are depleted, and neurones undergo gliosis. As pituitary adenomas do not present with DI, the coexistence of DI with a sellar mass suggests an alternative diagnosis, such as craniopharyngioma, pinealoma or germinoma, or a granulomatous process. Metastases from distant tumours are occasionally found in the pituitary stalk. Most are asymptomatic, but if they do cause hormonal disturbances, CDI is the commonest manifestation.
Diabetes insipidus occurs in the acute phase of TBI in 20% of cases, 2, 3 and in 15% of patients with SAH. 4 DI is almost always transient, and in both conditions, persistent DI is associated with worse prognosis; persistent DI is a common manifestation of increasing intracranial pressure and may presage the onset of coning. 3 Careful follow-up shows that DI persists in only 7% of TBI survivors, most of whom do not have polyuria which needs treatment with desmopressin.
5
In panhypopituitarism, DI may not initially clinically manifest, as steroid deficiency impairs free water excretion. Polyuria may only be unmasked when coexisting cortisol deficiency is treated. 6 While traditionally up to 50% of cases of DI were considered to be idiopathic; 7 many of these are now thought to be autoimmune in nature. Early work by Scherbaum and Bottazzo demonstrated positive AVP cell antibodies in one-third of a cohort of patients with idiopathic DI recruited from a number of academic centres in London. 8 They later reported rates of overt autoimmune disease in 28% of a similar cohort, and similar rates were subsequently confirmed by other groups; pernicious anaemia and thyroid disease are most common.
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| Adipsic DI
Adipsic DI is a rare disorder, characterized by AVP deficiency which is complicated by failure to generate thirst sensation in response to hypernatraemia. Loss of thirst sensation leads to inadequate compensatory water intake, which renders the patient vulnerable to significant hypernatraemia. Adipsic DI is classically described following neurosurgical clipping of anterior communicating artery (ACOM)
aneurysms following SAH, as the osmoreceptors in the hypothalamus derive their vascular supply from small perforating branches of the ACOM. 12 It is also relatively common after extensive surgery for large craniopharyngiomas 13 and occasionally after surgery for suprasellar tumours, or after neurosarcoidosis, 14 or TBI. 12 Recovery of thirst is unusual, with few well-documented cases in the literature. The clinic plasma sodium concentration can give useful clues to the differential diagnosis. Although plasma sodium is almost always normal at diagnosis in CDI, plasma concentrations at the upper end of the normal reference range are more usual in CDI than in PP. In contrast, as PP patients need to lower plasma osmolality to below the osmotic threshold for AVP secretion 16 in order to produce polyuria, plasma sodium in PP patients is almost invariably at the lower end of the reference range.
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| D IAG NOS IS OF CENTR AL D IAB E TE S INS IPIDUS
| History and clinical examination
It is rarely possible to make an outpatient differential diagnosis between CDI, NDI and PP because of the substantial crossover of baseline measurements of plasma sodium, osmolality and urine osmolality. In the majority of cases, the differential diagnosis of polyuria therefore requires dynamic testing of the AVP-renal axis, of which both indirect and direct methods are possible.
| Indirect tests
The most commonly used test for DI is the two-step water deprivation test. The first step is an 8-hour period of water deprivation; the physiological basis for this step is that dehydration stimulates the secretion of vasopressin, with consequent reduction in free water clearance. Urine volumes fall and urine osmolality should rise to over 750 mOsm/kg, provided that a sufficient osmotic stimulus to AVP secretion (plasma osmolality > 295 mosm/kg) is attained at the conclusion of dehydration. This step should differentiate patients with primary polydipsia, in whom vasopressin secretion and function are normal, from patients with either central and nephrogenic diabetes insipidus, who do not concentrate urine at the end of dehydration.
The second part of the test is designed to differentiate central diabetes insipidus from nephrogenic diabetes insipidus. Desmopressin (dDAVP), an AVP analogue, is administered by intramuscular or subcutaneous injection, and the urine osmolality response is measured.
As patients with central DI are simply missing AVP, they respond to exogenous desmopressin with a rise in urine osmolality to over Central DI >293 <300 >750
Nephrogenic DI >293 <300 <300
Partial DI or primary polydipsia >293
300-750 <750
Responses to water deprivation and subsequent dDAVP in central DI, nephrogenic DI and primary polydipsia.
TA B L E 2 Interpretation of WDT
should also have interim urgent electrolyte measurements. Water deprivation tests require careful supervision to ensure that surreptitious drinking does not occur, particularly in patients with suspected dipsogenic DI.
While the water deprivation test may differentiate between PP, CDI and NDI in classical and complete cases, a number of osmoregulatory subtleties make differentiation between PP, partial CDI and NDI challenging.
1. Subjects with long-standing polydipsia may not concentrate urine after administration of dDAVP. Prolonged suppression of AVP secretion, by chronic overdrinking means that V2 receptor stimulation does not occur, and pre-formed AQ-2 is scarce.
As a result, some patients with PP do not respond to endogenous or exogenous antidiuretic hormone, and can be misclassified as partial NDI. 17 2. In patients with partial CDI, lower than normal AVP concentrations can lead to urinary concentration, 18 possibly due to upregulation of V2 receptors.
3. In NDI, high AVP concentrations achieved in WDT can partially overcome renal resistance to AVP, resulting in concentration of urine > 300 mOsm/kg, leading to diagnostic confusion. 19 As a consequence, an overlap in results between patients with PP, CDI and NDI leads to uncertain diagnostic accuracy of the WDT. It should be further noted that the diagnostic criteria recommended for interpretation of the WDT are based on only 36 patients. 20 Until recently, the sensitivity and specificity of the results of the WDT had not been validated, but a recent prospective study showed that the correct diagnosis was made in only 70% of patients. In patients with primary polydipsia, the correct diagnosis was made in only 41% of cases. subnormal AVP responses are diagnostic of CDI. 27 Patients with severe AVP deficiency may become hypernatraemic during this test, which should only be performed under specialist supervision.
| Measurement of copeptin
As the technical issues of plasma AVP measurements are substantial, the measurement of plasma copeptin has been proposed as a sur- predict CDI. 30 The same group have also demonstrated, in a prospective multicenter study, that a post-transsphenoidal surgery copeptin concentration of <2.5 pmol/L had a predictive value of 81%
for CDI, with a specificity of 97%.
31
In a prospective study of 55 patients, the Swiss group further demonstrated that a baseline plasma copeptin concentration of >21.4 pmol/L differentiates NDI from other causes of polyuria, with a sensitivity and specificity of 100%, thus mitigating the need for WDT in this circumstance. Conversely, a baseline copeptin <2.6 pmol/L diagnoses complete CDI with 95% sensitivity and 100% specificity. In cases where baseline copeptin is 2.6-21.4 pmol/L, an osmotically stimulated copeptin concentration >4.9 pmol/L reliably discriminated between PP and cDI. 32 In their follow-up, much larger, study published earlier this year in the NEJM (n = 156), this pre-determined stimulated copeptin cut-off of 4.9 pmol/L had a 93% sensitivity and 100% specificity to distinguish between primary polydipsia and CDI. The overall diagnostic accuracy of the hypertonic saline test was 96%, far superior to that of the WDT, 77%, the main caveat being a higher rate of reported adverse events related to the hypertonic saline test. 33 The addition of copeptin to the standard WDT did not improve its diagnostic accuracy.
In summary, copeptin is a promising marker of plasma AVP concentration, which offers a convenient, rapid and sensitive diagnostic tool for polyuric states. The assay should be manageable in most reputable laboratories so that it is likely to replace measurement of plasma AVP in routine diagnostic practice.
| Measurement of thirst
Measurement of thirst, using a simple 10 cm long, unmarked visual analogue scale, has shown in physiological studies that thirst onset occurs at the same osmotic threshold as for AVP secretion. 16 Thirst is rapidly switched off by drinking, 34 even though hyperosmolarity persists. The characteristics of osmoregulated thirst are surprisingly reproducible within an individual, though there is considerable intraindividual variation. 35 Thirst responses in CDI show a physiological pattern of linear elevation during osmotic stimulation, and suppression after drinking. 36 Measurement of thirst is of diagnostic value in two scenarios. In adipsic DI, the demonstration of absent osmoregulated thirst during WDT or hypertonic saline infusion is the gold standard for diagnosis of the condition. 12, 36 In addition, patients with primary polydipsia have three clearly defined abnormalities of thirst; a low osmotic threshold for thirst, exaggerated thirst responses to elevation of plasma osmolality, and failure to suppress thirst during drinking, after osmotic stimulation. 37 It is the last of these three abnormalities which is diagnostically helpful, as failure to suppress thirst by more than 50% of stimulated levels, after drinking, is the strongest diagnostic indicator of primary polydipsia (Thompson CJ, unpublished observations).
| FURTHER INVE S TI G ATI ON S
Once a diagnosis of CDI is made, MRI imaging of the hypothalamopituitary region is required to establish whether there is a structural lesion which is responsible for AVP deficiency. It is important to note that lesions such as histiocytosis and germinoma may not manifest on the initial scans; normal imaging should be repeated within 6 months. 38 More frequent imaging is recommended in children with isolated DI, in whom germ cell tumours are more likely. 39 Elevated serum and CSF AFP and BHCG may serve as markers for germ cell tumours, although they do lack sensitivity. 40 Germinomas may present with normal AFP levels in both serum and CSF, and normal or mildly elevated BHCG levels. two-thirds of cases. 11 In addition, as the intensity of the physiological bright spot attenuates with age, the absence of signal may occur in 20% of the elderly population. 44 The 
| A SS E SS MENT OF AD IPS IC D I
Adipsic DI usually occurs in patients who have structural damage to the anterior hypothalamus where the osmoreceptors are situated.
It has most often been reported following after clipping of anterior communicating aneurysms or after extensive surgery for craniopharyngiomas, though a wide variety of aetiologies have been reported in the literature. 45 The hypothalamic damage is not confined to the osmoreceptors; a number of other hypothalamic abnormalities coexist with the DI, including obstructive sleep apnoea, hypothalamic obesity, abnormal temperature regulation and seizure disorders. 
| TRE ATMENT
Treatment of diabetes insipidus involves replacement of the free water deficit, replacement of the deficient hormone (in the case of CDI), and treatment of the underlying condition. AVP has a half-life in plasma of 5-10 minutes, too short for practical use. dDAVP is a synthetic analogue specific for the V2 receptor, which has been modified from AVP in two ways; the amino group of the cysteine has been removed to prolong half-life, 46 and d-arginine has been substituted for l-arginine to eliminate pressor activity. 47 It is available in parenteral, oral and nasal forms; the bioavailability of the parenteral form is 100 times that of the oral form, so that typical doses are 1-4 μg subcutaneously and 100-400 μg when given orally. The nasal form has a quicker onset of action; however, its effectiveness may be reduced if there is nasal mucosa inflammation. Most patients prefer the oral preparation as the more convenient option. The paper additionally reported that 5% of patients had been admitted to hospital with hyponatraemia secondary to dDAVP therapy, so the effects of over-treatment are not trivial. The key to avoiding hyponatraemia is to allow regular periods of free water clearance, so that excess water does not build up. There are several ways to achieve this;
| Acute DI
1. To delay a dose of dDAVP once or twice per week to allow an aquaresis to occur. The patient waits until an aquaresis has established-two or three visits to the toilet-and then they take the subsequent tablet. This is highly effective, and is the most popular with patients.
2. To delay each tablet of desmopressin until a slight aquaresis is evident. This method is extremely effective as there is a constant renal clearance of excess water. Some patients prefer a regular minor inconvenience to having to set aside an entire morning during which they pay several visits to the bathroom.
3. To omit a tablet once a week. This is an effective method, but patients are reluctant to submit themselves to an entire day of polyuria.
In ambulant patients, hypernatraemia is almost exclusively a complication seen in adipsic DI; it is very rare in the vast majority of patients with intact thirst. In Behan's study, patients with abnormal thirst were much more likely to develop significant hypernatraemia as out-patients, when compared to patients with intact thirst appreciation (20% vs 1.4%, P = 0.02). should also be avoided, as this can lead to hyponatraemia due to the non-suppressibility of the antidiuretic effect of dDAVP.
Another scenario which warrants special mention is alcohol consumption, in particular beer drinkers who may quickly consume large volumes of hypotonic fluid. In healthy individuals, ethanol suppresses AVP secretion, leading to an aquaresis; this suppression does not occur in dDAVP-treated patients, leaving them at risk of dilutional hyponatraemia. 
| CON CLUS ION
